Back to search

Peptide record

TPDB92623

Test peptide Anticancer Neuropeptide standard
5 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB92623
Test peptide
Anticancer Neuropeptide
Cancer-related peptides Neuroactive peptides
CancerPPD 2.0 Peptipedia
standard
No
A 5-aa standard natural multi-activity (Anticancer and Neuropeptide) peptide sequence curated from CancerPPD 2.0 and Peptipedia, with an available 3D structural model.
C-terminal: Amidation
Sequence
YSFGL-NH2
Physicochemical Analysis
C29H39N5O8
ARNDCEQHIKMPTWV
GLFSY
585.66
5.94
0
0
3
-0
-2.49
0.820
78.00
Mammalian: 2.8 hour Yeast: 10 min E.coli: 2 min
1490
254.41
2
Residue Composition
number
0
A
0
R
0
N
0
D
0
C
0
E
0
Q
1
G
0
H
0
I
1
L
0
K
0
M
1
F
0
P
1
S
0
T
0
W
1
Y
0
V
Amino Acid Distribution
A: 0 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 0 I: 0 L: 1 K: 0 M: 0 F: 1 P: 0 S: 1 T: 0 W: 0 Y: 1 V: 0
Chemical Descriptors
5
C29H39N5O8
585.66
5.94
-0
-2.49
0.820
Amidation
L
Linear
Free
Anti cancer
Neuropep Peptide
Evidence Records 2 records
Evidence 1 Activity

Activity

IC50
IC50 = 26.417±0.660 µM
Anticancer
26.417

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT assay
48 h

Source & Reference

CancerPPD 2.0
CancerPPD2
2023

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 39.047±0.770 µM
Anticancer
39.047

Target

Lung Cancer
MDA-MB-231
Lung

Assay & Model

MTT assay
48 h

Source & Reference

CancerPPD 2.0
CancerPPD2
2023